IDEAYA Biosciences, Inc. (IDYA) Stock Analysis and Metrics

IDEAYA Biosciences

NASDAQ: IDYA

$35.39 ▼ -0.84 (-2.32%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap3.15 Bn

P/E-7.27

P/S13.54

Div. Yield0.00

Add ratio to table…

About

IDEAYA Biosciences, Inc. is a precision medicine oncology company dedicated to the discovery development and commercialization of transformative therapies for cancer. The company integrates small molecule drug discovery structural biology and bioinformatics with internal capabilities to identify and validate translational biomarkers. This approach enables the creation of targeted therapies that are aligned to the genetic drivers of disease. Its pipeline currently includes 9 potential 1st in class product candidates across 4 clinical focus areas: darovasertib for uveal melanoma ADC and DNA damage response combinations MTAP pathway and next generation therapies. The company’s mission is to bring forth the next wave of precision oncology therapies that are more selective more effective and deeply personalized with the goal of altering the disease course and improving clinical outcomes for patients with cancer.

The company generates revenue primarily through upfront payments milestone payments and potential royalties from licensing and collaboration agreements with pharmaceutical partners. In August 2025 Ideaya received a $210 million upfront payment from Servier for exclusive rights to develop and commercialize darovasertib outside the United States and is eligible for up to an additional $320 million in development regulatory and commercial milestone payments as well as royalties on net sales in those territories. Earlier the company obtained an upfront payment from Novartis for the darovasertib license and is entitled to milestone payments and tiered royalties on worldwide sales. Collaboration agreements with Pfizer Gilead Hengrui Pharma and Biocytogen may also generate further payments as milestones are achieved. No product sales have been reported to date because the company’s therapies remain in clinical development.

The company operates through the following segments: Darovasertib for Uveal Melanoma, ADC and DNA Damage Response Combinations, MTAP Pathway, and Next Generation Therapies.

• Darovasertib for Uveal Melanoma: Darovasertib is an oral selective protein kinase C inhibitor being developed for uveal melanoma a rare ocular cancer in which approximately 95% of patients have activating mutations in GNAQ or GNA11 that drive protein kinase C signaling. The company is conducting multiple clinical trials including the Phase 2/3 OptimUM 02 trial that evaluates darovasertib in combination with crizotinib in 1st line metastatic disease with an expected readout in the 1st quarter of 2026 that could support an accelerated approval filing in the United States. In addition the neoadjuvant OptimUM 10 trial and adjuvant OptimUM 11 trial are underway to assess the drug’s potential in earlier disease settings.

• ADC and DNA Damage Response Combinations: This segment focuses on topoisomerase I inhibitor based antibody drug conjugates such as DLL3 targeted IDE849 and B7H3/PTK7 targeted IDE034 combined with PARG inhibition for example IDE161 to enhance antitumor activity in small cell lung cancer neuroendocrine carcinoma and other solid tumors. IDE849 is being evaluated by Hengrui Pharma in a Phase 1 trial in China with initial data showing activity in patients with brain metastasis. IDE034 has received IND clearance from the FDA and a 1st patient is expected in the 1st quarter of 2026. IDE161 has received IND clearance from the FDA and is being prepared for a Phase 1 combination trial with IDE849 in the 2nd quarter of 2026.

• MTAP Pathway: This segment develops MAT2A inhibitors such as IDE397 alone or in combination with Trop 2 directed ADC Trodelvy or MTA cooperative PRMT5 inhibitors such as IDE892 to exploit synthetic lethality in tumors with methylthioadenosine phosphorylase deletions including urothelial and non small cell lung cancer. The company is conducting a Phase 1/2 trial with Gilead to evaluate IDE397 in combination with Trodelvy in patients with MTAP deleted urothelial cancer and non small cell lung cancer. Initial data from the urothelial cancer cohort were presented in September 2025. IDE892 has received IND clearance and a Phase 1 dose escalation trial is planned for the 1st quarter of 2026.

• Next Generation Therapies: This segment pursues novel targets that counteract tumor heterogeneity and resistance such as dual KAT6/7 inhibition with IDE574 and WRN helicase inhibition with IDE275. IDE574 received IND clearance in January 2026 and a Phase 1 dose escalation trial is slated for the 1st quarter of 2026 in breast lung prostate and colorectal cancers. IDE275 was part of a collaboration with GSK which ended in March 2026 and the company now intends to complete the dose expansion portion of the Phase 1 trial to inform further development.

Ideaya Biosciences occupies a niche position in the precision oncology sector as it focuses on biomarker driven synthetic lethality and antibody drug conjugate combinations. Its competitive advantages include a proprietary discovery platform that integrates chemistry structural biology and bioinformatics and a pipeline of 1st in class candidates that target genetically defined patient populations. The company faces competition from larger pharmaceutical and biotechnology firms such as Immunocore which markets Tebentafusp for uveal melanoma and Amgen which developed Tarlatamab for DLL3 expressing tumors. Additionally numerous early stage biotech companies are pursuing similar synthetic lethality and ADC strategies. Ideaya’s collaborations with established partners like Pfizer Gilead and Servier provide access to resources expertise and commercial reach that help mitigate the resource gap. The company’s emphasis on early intervention in adjuvant and neoadjuvant settings further differentiates its approach from many competitors that focus primarily on advanced disease.

Since the company has not yet commercialized any product its prospective customers are patients with specific oncologic indications such as uveal melanoma small cell lung cancer neuroendocrine carcinoma urothelial carcinoma and non small cell lung cancer as well as the healthcare providers who will administer its therapies. Ideaya also interacts with pharmaceutical companies that serve as development and commercial partners for example Servier Pfizer Gilead Hengrui Pharma and Biocytogen. These collaborations provide funding expertise and potential pathways to market while the company retains rights to its therapies in certain territories.

Investment Thesis

▲ Bull case

IDEAYA Biosciences is positioned for transformative growth driven by the anticipated FDA approval of darovasertib combination for first-line HLA-A2-negative metastatic uveal melanoma, a high-unmet-need indication with no currently approved therapies, where the OptimUM-02 trial demonstrated a 58% reduction in disease progression risk (HR 0.42) and a median PFS improvement from 3.1 to 6.9 months, supported by a manageable safety profile and early OS trends, with the company targeting NDA completion in H2 2026 under the FDA's RTOR program, which could enable accelerated approval and rapid commercialization in a niche but commercially attractive patient population estimated at 1,500-2,000 new cases annually in the U.S. alone, with pricing potential exceeding $150,000 per patient annually based on comparable orphan oncology therapies.
The company's pipeline diversification beyond darovasertib offers significant near-term catalysts, including IDE034 (B7H3/PTK7 bispecific TOP1 ADC), which dosed its first patient in May 2026 triggering a $5 million milestone from Biocytogen, with preclinical data suggesting 30-40% co-expression in major solid tumors and limited normal tissue expression, positioning it as a potential first-in-class therapy with combination synergies observed with IDE161 (PARG inhibitor), and IDE574 (KAT6/7 dual inhibitor), which enrolled its first patient in April 2026 and targets ESR1-mutant breast cancer—a resistance mechanism affecting 10-50% of endocrine therapy patients—with preclinical evidence of superior antitumor activity versus KAT6-selective agents, while IDE892 (PRMT5 inhibitor) is advancing in MTAP-deleted solid tumors, including a new Roche collaboration for PDAC, addressing a pathway where 15-20% of NSCLC and up to 40% of pancreatic tumors harbor MTAP deletion with no approved therapies.
IDEAYA's financial resilience provides a durable foundation for execution, with $972.9 million in cash, cash equivalents, and marketable securities as of March 31, 2026, sufficient to fund operations through 2030 based on current burn rates, despite Q1 2026 net loss of $98.5 million, as collaboration revenue from Servier ($6.6 million in Q1) and potential milestones from ongoing partnerships (e.g., Biocytogen, Hengrui) offset R&D investments, and the company's strategic prioritization of high-potential assets—evidenced by deprioritizing non-core combinations like Trodelvy—ensures capital allocation to programs with the highest probability of technical and regulatory success, reducing dilution risk and enhancing long-term shareholder value creation.

IDEAYA Biosciences is positioned for transformative growth driven by the anticipated FDA approval of darovasertib combination for first-line HLA-A2-negative metastatic uveal melanoma, a high-unmet-need indication with no currently approved therapies, where the OptimUM-02 trial demonstrated a 58% reduction in disease progression risk (HR 0.42) and a median PFS improvement from 3.1 to 6.9 months, supported by a manageable safety profile and early OS trends, with the company targeting NDA completion in H2 2026 under the FDA's RTOR program, which could enable accelerated approval and rapid commercialization in a niche but commercially attractive patient population estimated at 1,500-2,000 new cases annually in the U.S. alone, with pricing potential exceeding $150,000 per patient annually based on comparable orphan oncology therapies.
The company's pipeline diversification beyond darovasertib offers significant near-term catalysts, including IDE034 (B7H3/PTK7 bispecific TOP1 ADC), which dosed its first patient in May 2026 triggering a $5 million milestone from Biocytogen, with preclinical data suggesting 30-40% co-expression in major solid tumors and limited normal tissue expression, positioning it as a potential first-in-class therapy with combination synergies observed with IDE161 (PARG inhibitor), and IDE574 (KAT6/7 dual inhibitor), which enrolled its first patient in April 2026 and targets ESR1-mutant breast cancer—a resistance mechanism affecting 10-50% of endocrine therapy patients—with preclinical evidence of superior antitumor activity versus KAT6-selective agents, while IDE892 (PRMT5 inhibitor) is advancing in MTAP-deleted solid tumors, including a new Roche collaboration for PDAC, addressing a pathway where 15-20% of NSCLC and up to 40% of pancreatic tumors harbor MTAP deletion with no approved therapies.
IDEAYA's financial resilience provides a durable foundation for execution, with $972.9 million in cash, cash equivalents, and marketable securities as of March 31, 2026, sufficient to fund operations through 2030 based on current burn rates, despite Q1 2026 net loss of $98.5 million, as collaboration revenue from Servier ($6.6 million in Q1) and potential milestones from ongoing partnerships (e.g., Biocytogen, Hengrui) offset R&D investments, and the company's strategic prioritization of high-potential assets—evidenced by deprioritizing non-core combinations like Trodelvy—ensures capital allocation to programs with the highest probability of technical and regulatory success, reducing dilution risk and enhancing long-term shareholder value creation.

▼ Bear case

IDEAYA Biosciences faces significant regulatory and execution risks in its lead darovasertib program, as the OptimUM-02 trial's overall survival data remains immature, with only an early trend observed, and the FDA's RTOR pathway, while efficient, does not guarantee approval, especially given the trial's reliance on PFS as a surrogate endpoint in a rare disease where historical approvals have sometimes required OS benefit, and the combination's safety profile includes Grade 3+ adverse events like diarrhea, syncope, and hypotension in the single-digit% range, which could limit real-world adoption despite manageable tolerability, while the uveal melanoma market is inherently small, with only ~3,000 new U.S. cases annually and ~50% progressing to metastatic disease, constraining peak sales potential even with premium pricing.
The company's pipeline is heavily dependent on early-stage, unproven mechanisms with substantial clinical uncertainty, as IDE034, IDE574, and IDE892 are all in Phase 1 development, and despite promising preclinical data, historical failure rates for bispecific ADCs and epigenetic inhibitors in oncology exceed 70% due to lack of therapeutic window or unexpected toxicity, and IDEAYA's reliance on combination strategies—such as IDE034 with IDE161 or IDE892 with IDE397/RG6505—adds complexity, as dual-agent regimens face higher hurdles in demonstrating added value over monotherapy, and the MTAP-deleted opportunity, while biologically compelling, remains unvalidated in humans, with no approved therapies to date and prior PRMT5 inhibitors struggling with thrombocytopenia and other dose-limiting toxicities that may impede IDE892's development.
IDEAYA's cash runway, while currently strong at ~$973 million, is vulnerable to accelerated depletion if clinical programs encounter delays or failures, as R&D expenses rose to $95.7 million in Q1 2026 from $86.6 million in Q4 2025 due to higher clinical trial and personnel costs, and with multiple Phase 1/2 trials advancing simultaneously, any setback in key assets like darovasertib (e.g., FDA requesting additional data) or IDE034 (e.g., safety signals in dose escalation) could trigger costly trial extensions or redundancies, and the company's dependence on collaboration revenue—though currently supported by Servier—creates uncertainty if milestones are delayed or partnership terms shift, while ongoing stock-based compensation expense ($14.5 million in Q1 2026) continues to dilute shares, with basic and diluted shares outstanding rising from 88.6 million to 88.7 million quarter-over-quarter, potentially pressuring EPS if revenue growth does not materialize soon.

IDEAYA Biosciences faces significant regulatory and execution risks in its lead darovasertib program, as the OptimUM-02 trial's overall survival data remains immature, with only an early trend observed, and the FDA's RTOR pathway, while efficient, does not guarantee approval, especially given the trial's reliance on PFS as a surrogate endpoint in a rare disease where historical approvals have sometimes required OS benefit, and the combination's safety profile includes Grade 3+ adverse events like diarrhea, syncope, and hypotension in the single-digit% range, which could limit real-world adoption despite manageable tolerability, while the uveal melanoma market is inherently small, with only ~3,000 new U.S. cases annually and ~50% progressing to metastatic disease, constraining peak sales potential even with premium pricing.
The company's pipeline is heavily dependent on early-stage, unproven mechanisms with substantial clinical uncertainty, as IDE034, IDE574, and IDE892 are all in Phase 1 development, and despite promising preclinical data, historical failure rates for bispecific ADCs and epigenetic inhibitors in oncology exceed 70% due to lack of therapeutic window or unexpected toxicity, and IDEAYA's reliance on combination strategies—such as IDE034 with IDE161 or IDE892 with IDE397/RG6505—adds complexity, as dual-agent regimens face higher hurdles in demonstrating added value over monotherapy, and the MTAP-deleted opportunity, while biologically compelling, remains unvalidated in humans, with no approved therapies to date and prior PRMT5 inhibitors struggling with thrombocytopenia and other dose-limiting toxicities that may impede IDE892's development.
IDEAYA's cash runway, while currently strong at ~$973 million, is vulnerable to accelerated depletion if clinical programs encounter delays or failures, as R&D expenses rose to $95.7 million in Q1 2026 from $86.6 million in Q4 2025 due to higher clinical trial and personnel costs, and with multiple Phase 1/2 trials advancing simultaneously, any setback in key assets like darovasertib (e.g., FDA requesting additional data) or IDE034 (e.g., safety signals in dose escalation) could trigger costly trial extensions or redundancies, and the company's dependence on collaboration revenue—though currently supported by Servier—creates uncertainty if milestones are delayed or partnership terms shift, while ongoing stock-based compensation expense ($14.5 million in Q1 2026) continues to dilute shares, with basic and diluted shares outstanding rising from 88.6 million to 88.7 million quarter-over-quarter, potentially pressuring EPS if revenue growth does not materialize soon.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password